FCCC LOGO Faculty Publications
Mohler JL , Antonarakis ES , Armstrong AJ , D'Amico AV , Davis BJ , Dorff T , Eastham JA , Enke CA , Farrington TA , Higano CS , Horwitz EM , Hurwitz M , Ippolito JE , Kane CJ , Kuettel MR , Lang JM , McKenney J , Netto G , Penson DF , Plimack ER , Pow-Sang JM , Pugh TJ , Richey S , Roach M , Rosenfeld S , Schaeffer E , Shabsigh A , Small EJ , Spratt DE , Srinivas S , Tward J , Shead DA , Freedman-Cass DA
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
J Natl Compr Canc Netw. 2019 May 1;17(5) :479-505
Back to previous list
Abstract
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.
Notes
1540-1413 Mohler, James L Antonarakis, Emmanuel S Armstrong, Andrew J D'Amico, Anthony V Davis, Brian J Dorff, Tanya Eastham, James A Enke, Charles A Farrington, Thomas A Higano, Celestia S Horwitz, Eric Mark Hurwitz, Michael Ippolito, Joseph E Kane, Christopher J Kuettel, Michael R Lang, Joshua M McKenney, Jesse Netto, George Penson, David F Plimack, Elizabeth R Pow-Sang, Julio M Pugh, Thomas J Richey, Sylvia Roach, Mack Rosenfeld, Stan Schaeffer, Edward Shabsigh, Ahmad Small, Eric J Spratt, Daniel E Srinivas, Sandy Tward, Jonathan Shead, Dorothy A Freedman-Cass, Deborah A Journal Article Practice Guideline United States J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023.